Jazz Pharmaceuticals Gets European Commission OK for Enrylaze
By Ben Glickman
Jazz Pharmaceuticals on Thursday said it had received market authorization from the European Commission for its treatment for certain types of leukemia and lymphoma.
The Dublin-based pharmaceutical company said that Enrylaze could now be used as a component of a multi-agent chemotherapeutic regiment in the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma.
Enrylaze is currently approved under the name Rylaze in the U.S. and Canada.
The approval from the European Commission was based on Phase 2/3 trial data.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 21, 2023 18:05 ET (22:05 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst